NCT01572545View on ClinicalTrials.gov

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass

NACompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

January 31, 2013

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Denosumab

Denosumab (injection), 60 mg, administered as a single subcutaneous injection once

DRUG

Zoledronic acid

Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion

Trial Locations (3)

Unknown

251 Hellenic Air Force Hospital, Athens

424 General Military Hospital, Thessaloniki

Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki

All Listed Sponsors
collaborator

424 General Military Hospital

OTHER

collaborator

251 Hellenic Air Force & VA General Hospital

OTHER

lead

Aristotle University Of Thessaloniki

OTHER

NCT01572545 - Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass | Biotech Hunter | Biotech Hunter